Ranitidine is associated with infections, necrotizing enterocolitis, and fatal outcome in newborns.
Abstract
BACKGROUND AND OBJECTIVES
Gastric acidity is a major nonimmune defense mechanism against infections. The objective of this study was to investigate
whether ranitidine treatment in very low birth weight (VLBW) infants is associated with an increased risk of infections, necrotizing
enterocolitis (NEC), and fatal outcome.
METHODS
Newborns with birth weight between 401 and 1500 g or gestational age between 24 and 32 weeks, consecutively observed in neonatal
intensive care units, were enrolled in a multicenter prospective observational study. The rates of infectious diseases, NEC,
and death in enrolled subjects exposed or not to ranitidine were recorded.
RESULTS
We evaluated 274 VLBW infants: 91 had taken ranitidine and 183 had not. The main clinical and demographic characteristics
did not differ between the 2 groups. Thirty-four (37.4%) of the 91 children exposed to ranitidine and 18 (9.8%) of the 183
not exposed to ranitidine had contracted infections (odds ratio 5.5, 95% confidence interval 2.9-10.4, P < .001). The risk
of NEC was 6.6-fold higher in ranitidine-treated VLBW infants (95% confidence interval 1.7-25.0, P = .003) than in control
subjects. Mortality rate was significantly higher in newborns receiving ranitidine (9.9% vs 1.6%, P = .003).
CONCLUSIONS
Ranitidine therapy is associated with an increased risk of infections, NEC, and fatal outcome in VLBW infants. Caution is
advocated in the use of this drug in neonatal age.
Links
Authors
Terrin G, Passariello A, De Curtis M, Manguso F, Salvia G, Lega L, Messina F, Paludetto R, Canani RB
Institution
Department of Women’s Health and Territorial Medicine, University La Sapienza, Rome, Italy.
Source
Pediatrics 129:1 2012 Jan pg e40-5MeSH
Anti-Ulcer AgentsBacterial Infections
Enterocolitis, Necrotizing
Female
Gastric Acid
Histamine H2 Antagonists
Humans
Infant, Newborn
Infant, Premature
Infant, Premature, Diseases
Infant, Very Low Birth Weight
Male
Peptic Ulcer
Ranitidine
Risk Factors
Pub Type(s)
Journal ArticleLanguage
eng
PubMed ID
22157140
Log In

